325 related articles for article (PubMed ID: 26086967)
1. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
2. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
3. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.
Bykov VJ; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG
Front Oncol; 2016; 6():21. PubMed ID: 26870698
[TBL] [Abstract][Full Text] [Related]
4. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Ceder S; Eriksson SE; Cheteh EH; Dawar S; Corrales Benitez M; Bykov VJN; Fujihara KM; Grandin M; Li X; Ramm S; Behrenbruch C; Simpson KJ; Hollande F; Abrahmsen L; Clemons NJ; Wiman KG
EMBO Mol Med; 2021 Feb; 13(2):e10852. PubMed ID: 33314700
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
6. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants.
Nagourney AJ; Gipoor JB; Evans SS; D'Amora P; Duesberg MS; Bernard PJ; Francisco F; Nagourney RA
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981018
[No Abstract] [Full Text] [Related]
8. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
9. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
[TBL] [Abstract][Full Text] [Related]
10. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
[TBL] [Abstract][Full Text] [Related]
11. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.
Michaeli O; Luz I; Vatarescu M; Manko T; Weizman N; Korotinsky Y; Tsitrina A; Braiman A; Arazi L; Cooks T
Cell Death Dis; 2024 Jun; 15(6):426. PubMed ID: 38890278
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Degtjarik O; Golovenko D; Diskin-Posner Y; Abrahmsén L; Rozenberg H; Shakked Z
Nat Commun; 2021 Dec; 12(1):7057. PubMed ID: 34862374
[TBL] [Abstract][Full Text] [Related]
13. Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).
Gallo D; Fruscella E; Ferlini C; Apollonio P; Mancuso S; Scambia G
Int J Gynecol Cancer; 2006; 16(1):222-30. PubMed ID: 16445637
[TBL] [Abstract][Full Text] [Related]
14. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
15. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
Kupryjanczyk J; Kraszewska E; Ziolkowska-Seta I; Madry R; Timorek A; Markowska J; Stelmachow J; Bidzinski M;
BMC Cancer; 2008 Jan; 8():27. PubMed ID: 18230133
[TBL] [Abstract][Full Text] [Related]
16. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
18. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
19. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
